At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Jul 1, 2026 at 09:06 ET
Abivax priced an upsized $800M public offering of 6.4M ADSs at $125 per ADS, a 2.4% premium to VWAP, representing 8% dilution. Proceeds will fund commercialization of lead drug obefazimod and extend cash runway into Q2 2029. The pricing and upsize indicate strong demand, but dilution is a near-term negative.
- Offering of 6.4M ADSs at $125/ADS raised $800M gross (upsized from $600M)
- Priced at 2.39% premium to 3-day VWAP
- 8% dilution (9.2% if underwriters' option exercised in full)
- Cash runway extended from Q4 2027 to Q2 2029
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access